Erlotinib for Treatment of Psoriasis

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT01006096
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • erlotinib — DRUG
    100mg tablet, once daily for 16 weeks
  • placebo tablet — OTHER
    placebo tablet (lactose), once daily for 16 weeks

Study Details

The purpose of this study is to determine whether erlotinib is effective in the treatment of psoriasis.

Key Dates

First listed
Nov 2, 2009
Status verified
Nov 2014

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Erlotinib
  • Placebo Comparator: Placebo tablets

Primary Outcome Measure

To determine efficacy of erlotinib in treatment of moderate to severe psoriasis measured by the Psoriasis Area and Severity Index (PASI) and the Physician's Global Assessment (PGA). [ Time Frame: week 4, 8, 12, 16, and 24 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Northwestern University Feinberg School of Medicine Department of DermatologyChicagoIllinois60611-

Find similar trials in Chicago, IL

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Northwestern University Feinberg School of Medicine Department of Dermatology· Chicago, IL

Related Studies